13D Filings
CASI Pharmaceuticals, Inc.
CASI
Amendment
Ownership

6.40%

Total Shares

992,638

Issuer CIK

1962738

CUSIP

G1933S101

Event Date

Dec 29, 2024

Accepted

Feb 3, 2025, 08:17 PM

Reporting Persons (6)
Joint Filing

This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.

NameType% of ClassAggregateSole VotingShared Voting
Quan Zhou
Individual
6.40%992,63876,788915,850
IDG-Accel China Growth Fund III L.P.
Partnership
5.90%915,850855,22260,628
IDG-Accel China III Investors L.P.
Partnership
5.90%915,85060,628855,222
IDG-Accel China Growth Fund III Associates L.P.
Partnership
5.90%915,850855,22260,628
IDG-Accel China Growth Fund GP III Associates Ltd.
CO
5.90%915,850915,8500
Ho Chi Sing
Individual
5.90%915,8500915,850
Disclosure Items (3)

Security Title

Ordinary Shares, $0.0001 par value

Issuer Name

CASI Pharmaceuticals, Inc.

Issuer Address

1701-1702, CHINA CENTRAL OFFICE TOWER 1,, BEIJING, F4, 100025

In December 2024, in a series of open market purchases, IDG-Accel Growth purchased additional 57,869 Ordinary Shares in total with an aggregate purchase price of $180,972.10 (including commission fee), and IDG-Accel Investors purchased additional 4,102 Ordinary Shares in total with an aggregate purchase price of $12,723.89 (including commission fee). The source of funds for such purchases was the available capital of IDG-Accel Growth and IDG-Accel Investors, which may, at any given time, include margin loans made by brokerage firms or unsecured borrowings under a working capital credit line, each in the ordinary course of business.

Percentage of Class

Item 5(a) of the Original Schedule 13D is hereby amended and restated in its entirety as follows: (a) Each of the Reporting Persons' current ownership in the Issuer and the Ordinary Shares is set forth on the cover pages to this Statement on Schedule 13D and is incorporated by reference herein. The ownership percentage appearing on such pages has been calculated based on a total of 15,492,581 Ordinary Shares outstanding as of December 18, 2024, as disclosed in the Issuer's registration statement on Form F-3 filed with the SEC on December 20, 2024. The Reporting Persons disclaim membership in any "group" with any person other than the Reporting Persons. The filing of this Statement on Schedule 13D by the Reporting Persons shall not be considered an admission that such Reporting Persons, for the purpose of Section 13(d) of the Exchange Act, are the beneficial owners of any of the Ordinary Shares covered in this Statement on Schedule 13D, and the Reporting Persons expressly disclaim such beneficial ownership.

Number of Shares

Item 5(b) of the Original Schedule 13D is hereby amended and restated in its entirety as follows: (b) The following table sets forth the beneficial ownership of Ordinary Shares for each of the Reporting Persons. Reporting Person Number of Percentage Sole Power Shared Sole Power to Shared Ordinary of to Power to Dispose/Direct Power Shares Ordinary Vote/Direct Vote/Direct Disposition to Beneficially Shares Vote Vote Dispose/ Owned Direct Disposition IDG-Accel Growth 915,850 5.9% 855,222 60,628 855,222 60,628 IDG-Accel Investors 915,850 5.9% 60,628 855,222 60,628 855,222 IDG-Accel Associates 915,850 5.9% 855,222 60,628 855,222 60,628 IDG-Accel GP 915,850 5.9% 915,850 0 915,850 0 Chi Sing Ho 915,850 5.9% 0 915,850 0 915,850 Quan Zhou 992,638 6.4% 76,788 915,850 76,788 915,850

Transactions

Item 5(c) of the Original Schedule 13D is hereby amended and restated in its entirety as follows: (c) The following describes all transactions in the Issuer's Ordinary Shares that were effected by IDG-Accel Growth and IDG-Accel Investors respectively during the past 60 days by the Reporting Person: Transaction Date Nature of Price Per Quantity of Where/How Transaction Ordinary Ordinary Effected Share Shares IDG-Accel Growth 12/3/2024 Purchase 3.9422 4,669 Open Market 12/6/2024 Purchase 3.1250 1,964 Open Market 12/10/2024 Purchase 3.5219 4,669 Open Market 12/12/2024 Purchase 3.1501 4,669 Open Market 12/13/2024 Purchase 3.2317 4,669 Open Market 12/16/2024 Purchase 3.2018 4,669 Open Market 12/17/2024 Purchase 3.0511 4,669 Open Market 12/18/2024 Purchase 2.9460 4,669 Open Market 12/19/2024 Purchase 2.7796 4,669 Open Market 12/20/2024 Purchase 2.7359 4,669 Open Market 12/23/2024 Purchase 2.6219 4,359 Open Market 12/26/2024 Purchase 2.7700 187 Open Market 12/27/2024 Purchase 2.9793 4,669 Open Market 12/30/2024 Purchase 2.8977 4,669 Open Market IDG-Accel Investors 12/3/2024 Purchase 3.9422 331 Open Market 12/6/2024 Purchase 3.1250 139 Open Market 12/10/2024 Purchase 3.5219 331 Open Market 12/12/2024 Purchase 3.1501 331 Open Market 12/13/2024 Purchase 3.2317 331 Open Market 12/16/2024 Purchase 3.2018 331 Open Market 12/17/2024 Purchase 3.0511 331 Open Market 12/18/2024 Purchase 2.9460 331 Open Market 12/19/2024 Purchase 2.7796 331 Open Market 12/20/2024 Purchase 2.7359 331 Open Market 12/23/2024 Purchase 2.6219 309 Open Market 12/26/2024 Purchase 2.7700 13 Open Market 12/27/2024 Purchase 2.9793 331 Open Market 12/30/2024 Purchase 2.8977 331 Open Market

CASI Pharmaceuticals, Inc. — Schedule 13D | 13D Filings